Introduction
The venerable biotech Biogen (NASDAQ:BIIB) reported an upside surprise for Q3 Wednesday, as per its press release:
- Total revenues of $3.0 billion, a 6% increase versus the same quarter in the prior year.
- Growth was driven by a 10% increase in worldwide TECFIDERA® revenues as well as increased revenues from TYSABRI®, ELOCTATE®, ALPROLIX®, and BENEPALI®. Revenues were partially offset by a decrease in worldwide interferon sales.
- In the U.S., Biogen estimates that TECFIDERA benefited by approximately $40 million to $50 million versus prior quarter due to inventory build in the channel. Outside the U.S., third quarter 2016 TECFIDERA revenue decreased versus second quarter primarily due to parallel trade dynamics.
- Foreign exchange negatively impacted total revenues by approximately $54 million compared with the third quarter of 2015, driven by changes in hedge results.
- GAAP net income attributable to Biogen Inc. of $1.0 billion, a 7% increase versus the same quarter in the prior year.
- GAAP diluted earnings per share (EPS) of $4.71, a 13% increase versus the same quarter in the prior year.
At $1.034 B, quarterly sales of Tecfidera, for MS, were up about $100 MM from one year ago; thus inventory changes and, likely, price increases accounted for all the increase.

